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ABSTRACT 
 
Chemotherapy Induced Peripheral Neuropathy (CIPN) is a common problem among 
cancer patients who receive a wide range of chemotherapy. This problem causes a decline in 
quality of life and increased disabilities. CIPN assessment instruments are either subjective, 
objective, or a combination of both. So far, there is no agreement on the best way for assessment. 
The goal of this study was to explore the relationships among subjective and objective CIPN 
assessment instruments.  Specifically, this study aimed to 1) evaluate the relationship between 
the Total Neuropathy Score-reduced (mainly objective) and patients’ function, as measured by 
the interference scale of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool 
(subjective); and 2) evaluate the relationship between the Total Neuropathy Score-reduced and 
neuropathy symptom experience, as measured by the symptom experience scale of the 
Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (Subjective). To achieve those 
aims, a secondary data analysis for 56 participants who participated in a study entitled: Group 
Acupuncture for Treatment of Neuropathy from Chemotherapy was done. After Pearson 
correlations were calculated, the study found that there is a positive, weak relationship between 
the TNSr and the symptom experience scale of the CIPNAT(r=0.34). A positive, week 
relationship was found between the TNSr and the interference with activity scale of the 
CIPNAT(r=0.28). These results suggest that objective and subjective assessment are not highly 
correlated, and likely measure different aspects of CIPN. A comprehensive assessment approach 
is needed for decision making in the clinical oncology setting. 
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CHAPTER ONE: INTRODUCTION 
 
Chemotherapy Induced Peripheral Neuropathy (CIPN) is a common problem among 
cancer patients receiving chemotherapy for numerous types of cancers (Grisold, Cavaletti, & 
Windebank, 2012; Lavoie Smith, Cohen, Pett, & Beck, 2011; Smith, Cohen, Pett, & Beck, 
2010). The incidence varies from 10% to 100% depending on the chemotherapy agents used 
(Balayssac et al., 2011). These chemotherapies include but are not limited to: taxanes, platinums, 
bortezomib, thalidomide, lenolidamide, and vinca alkaloids (Argyriou, Cavaletti, Bruna, Kyritsis, 
& Kalofonos, 2014; Chaudhry, Cornblath, Polydefkis, Ferguson, & Borrello, 2008; Paice, 2009; 
Visovsky, 2003; Wolf et al., 2012). 
CIPN leads to sensory, motor, and autonomic deficits (Dermitzakis et al., 2016). Most of 
the symptoms are sensory and present with stocking and glove distribution causing numbness, 
tingling, discomfort and neuropathic pain (Cavaletti, Alberti, & Marmiroli, 2015; Dougherty, 
Cata, Burton, Vu, & Weng, 2007; Jaggi & Singh, 2012; Koeppen et al., 2004; Tofthagen, 
McAllister, & Visovsky, 2013). These symptoms start distally in the hands and feet moving 
proximally with cumulative chemotherapy doses (Dougherty, Cata, Cordella, Burton, & Weng, 
2004). Such symptoms, by their nature, are subjective and thus must be reported by the patient. 
Combined sensory, motor, and autonomic neuropathies negatively affect patients’  
quality of life, functional ability, sleep, and balance (Bakitas, 2007; Beijers, Mols, & 
Vreugdenhil, 2014; Beijers, Mols, Dercksen, Driessen, & Vreugdenhil, 2014; Binda et al., 2013; 
Calhoun et al., 2003; Driessen, de Kleine-Bolt, Vingerhoets, Mols, & Vreugdenhil, 2012; Hong, 
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Tian, & Wu, 2014; Kneis et al., 2015; Lane, 2005; Oerlemans et al., 2014; Park, Lin, & Kiernan, 
2012b; Smith, Beck, & Cohen, 2008). These devastating effects may lead clinicians to change 
the chemotherapy regimen or reduce the dose (Cavaletti et al., 2003; Kim, Dougherty, & Abdi, 
2015). Some of these problems, such as balance, can be assessed objectively by the clinicians. 
Chemotherapy induced peripheral neuropathy assessment instruments are either 
objective, subjective, or a combination of both. Objective instruments can use physical exam, 
sensory quantification such as using monofilaments and vibration sensation, direct nerve testing 
such as using skin biopsies, nerve ultrasound, nerve conduction studies (NCS), and nerve 
excitability assessment (NEA). Because of their complexities, insurance coverage, and provider 
comfort level, these instruments also are rarely used in the oncology clinical setting (Cornblath et 
al., 1999). 
Most CIPN assessment instruments are subjective and depend on patient reporting. 
 
Examples of these instruments are the Patient Neurotoxicity Questionnaire (Kuroi et al., 2008; 
Shimozuma et al., 2009), the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool 
(Tofthagen, McMillan, & Kip, 2011), The Functional Assessment of Cancer 
Therapy/Gynecologic Oncology Group Neurotoxicity scale (Calhoun et al., 2003; Griffith et al., 
2014; Yoo & Cho, 2014), the Chemotherapy Induced Neurotoxicity Questionnaire (CINQ) 
(Leonard et al., 2005), The Treatment-Induced Neuropathy Assessment Scale (TNAS) (Mendoza 
et al., 2015), the European Organization for Research and Treatment of Cancer EROTC-QOL- 
CIPN-20 (Cull et al., 2001; Lavoie Smith et al., 2013; Padman et al., 2015), the Peripheral 
Neuropathy Scale (Cavaletti et al., 2003; Cavaletti et al., 2007), and the Rasch-built Disability 
Scale for patients with CIPN (Binda et al., 2013). 
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These subjective instruments are important in understanding the symptoms and effects of 
CIPN on quality of life (QOL). Due to time constraints, unfamiliarity, and discrepancy between 
the provider and patient perception, these subjective instruments are rarely used in the clinical 
oncology setting either (Basch et al., 2012; Smith et al., 2014; Visovsky et al., 2012). 
Due to the assessment deficiencies of both the objective and the subjective instruments, 
using a combined objective/subjective instruments such as the Total Neuropathy Scores (TNS) 
and its various versions, may be a more feasible approach in the clinical setting, if they 
correspond well with patient symptoms. This instrument was initially reported for use in 
neuropathy in 1994 (Cavaletti et al., 2003). It underwent multiple studies and modifications to 
improve its reliability and validity (Binda, Cavaletti, Cornblath, Merkies, & group, 2015; 
Cavaletti et al., 2003; Lavoie Smith et al., 2011). 
Statement of the Problem 
 
CIPN is a grave problem affecting the quality of life for many cancer patients; thus, CIPN 
needs early detection to prevent long term damage. However, there is disagreement among 
clinicians on the best method for assessment in the clinical oncology setting (Izycki et al., 2016). 
Furthermore, the relationship between patients reported CIPN symptoms and clinical 
assessments such as the TNSr have not been adequately explored. Neurologists may depend 
mainly on objective measures such as nerve conduction studies and neurological examination 
and may overlook patients’ input. On the other hand, nursing researchers have relied more on 
subjective measures and patient reported outcomes, while oncologists have relied on the National 
Cancer Institute-Common Terminology Criteria (NCI-CTCAE) (Cavaletti et al., 2007).This 
disagreement on the best way to assess CIPN may make it hard to understand the problem of 
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CIPN in the clinical setting. Oncology practices need a unified approach to assessment of CIPN, 
so that clearer communication is possible among providers (Tanay, Armes, & Ream, 2016). 
The purpose of this study is to evaluate relationships among the Total Neuropathy Score- 
reduced, neuropathy symptoms, and function. If this instrument has a strong relationship with 
neuropathy symptoms and function, it can be used to help guide clinicians in treatment strategies 
such as chemotherapy treatment choice, dose reduction, or discontinuation of the neurotoxic 
chemotherapy thus preventing irreversible side effects and functional disabilities from CIPN. 
Also, it may assist providers in communicating with each other about patients. This study aims to 
evaluate the validity of the TNSr in assessment of neuropathy symptoms and function. 
Specific Aims 
 
The specific aims of this study were as follows: 
 
Aim 1: To evaluate the relationship between the Total Neuropathy Score-reduced and patients’ 
function, as measured by the interference scale of the Chemotherapy-Induced Peripheral 
Neuropathy Assessment Tool. 
Aim 2: To evaluate the relationship between the Total Neuropathy Score-reduced and 
neuropathy symptom experience, as measured by the symptom experience scale of the 
Chemotherapy-Induced Peripheral Neuropathy Assessment Tool. 
Significance to Nursing 
 
CIPN is a common problem among patients treated for cancer (Grisold et al., 2012). 
 
However, there is no widespread agreement on how to assess this pervasive problem (Izycki et 
al., 2016). If a strong relationship is found between the TNSr, neuropathy symptoms, and patient 
function it may have supported the validity of the TNSr for use with patients with CIPN. Such a 
valid instrument would be very beneficial to oncology nurse practitioner and oncology clinicians. 
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The TNSr is a short tool (using five items only). It addresses both the subjective patient input 
(symptom extension into the extremities), and addresses the objective clinician input (pin 
sensibility, vibration sensibility, muscle strength, and deep tendon reflexes). Studying this 
relationship contributes evidence of construct validity for this instrument as it connects the TNSr 
with some CIPN outcomes. Finding a strong relationship between TNSr, neuropathy symptoms, 
and patient function may lead to consistent and meaningful CIPN assessment. It may also help in 
early CIPN detection, leading to fewer complications, falls, and balance issues. It also may help 
researchers in evaluating new CIPN treatment modalities. 
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CHAPTER TWO: REVIEW OF THE LITERATURE 
 
This chapter reviews and summarizes the current literature on Chemotherapy Induced 
Peripheral Neuropathy (CIPN) assessment instruments. A literature search was conducted using 
the following search terms: chemotherapy induced peripheral neuropathy assessment, 
neuropathy, and polyneuropathy. The search was conducted using PUBMED. All articles that 
met inclusion criteria (indexed in PUBMED, written in the English language, used with human 
subjects, evaluating CIPN instrument reliability and validity, published between 2011 and 2017) 
were included. Literature review before 2011 is available in two comprehensive reviews 
(Griffith, Merkies, Hill, & Cornblath, 2010; Shimozuma et al., 2009). This chapter includes the 
conceptual framework, CIPN screening, objective CIPN instruments, subjective CIPN 
instruments, history of the Total Neuropathy Score in CIPN assessment, and CIPN assessment of 
patient function. 
Conceptual Framework 
 
Neuropathy, neurotoxicity, polyneuropathy, neuropathic pain in the presence of 
chemotherapy, and painful neuropathy are used in the literature as attributes of CIPN (Fallon et 
al., 2015; Gewandter et al., 2015; Koeppen, 2014; Kroigard et al., 2014; Wickham, 2007). CIPN 
can be conceptualized as having three major components: loss of sensation, exaggerated 
sensation, and functional disabilities (Tofthagen, Kip, Passmore, Loy, & Berry, 2016) (Figure 1). 
The loss of sensation can be clinically evaluated by pinprick, vibration, light touch, and joint 
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position sensations(Alberti et al., 2014), while exaggerated sensations include tingling, electric- 
like sensations, and neuropathic pain, which are primarily evaluated by patient report (Lavoie 
Smith et al., 2011; Tofthagen, 2010). Functional disabilities include but are not limited to 
driving, writing, picking things up, work, sleep, walking, hobbies, household duties, walking, 
cooking, and exercise (Binda et al., 2013; Tofthagen, 2010). 
Figure 1. Chemotherapy Induced Peripheral Neuropathy Conceptual Framework. 
 
 
 
 
Source: (Tofthagen et al., 2016). Used with permission. 
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CIPN Screening Instruments 
 
CIPN screening is needed before and during chemotherapy treatment (Simon, Danso, 
Alberico, Basch, & Bennett, 2017). This will help in early detection, CIPN treatment, and help in 
CIPN research. 
The National Cancer Institute-Common Toxicity Criteria (NCI-CTC) is a widely used 
neuropathy screening instrument (Basch et al., 2014; Chu, Lee, Lee, & Cleeland, 2015; Visovsky 
et al., 2012). It includes sensory and motor sections. This instrument is rated by the provider and 
ranges from 0 (Normal) to 4 (permanent sensory loss) in the sensory section or (paralysis) in the 
motor section (Kautio et al., 2011). This instrument has the advantage of being short and quick 
which made it the recommended instrument for clinical trials by the Food and Drug 
Administration (FDA) and the NCI. This instrument went through multiple modifications and 
name changes through the years to be called the Common Terminology Criteria for Adverse 
Events (CTCAE) and NCI-CTCAE (Miyoshi et al., 2015). Despite its easy usage, it lacks 
flexibility in score variance and lacks both patient input and clinical neurologic examination 
(Basch et al., 2014; Cavaletti et al., 2015). 
The reliability and the validity of the NCI-CTCAE were tested extensively. The kappa 
reliability coefficient was reported to be 0.98 (Miyoshi et al., 2015). Validity was evidenced as 
patients had higher scores with cumulative chemotherapy dosing (Pereira et al., 2016; Velasco et 
al., 2014). Further evidence of validity was reported by correlating it to the Total Neuropathy 
Score (TNS) and its different versions. Most of the studies reported moderate to high correlation 
with the sensory section (0.4 to 0.6) and low correlation with the motor section (0.25) (Alberti et 
al., 2014; Frigeni et al., 2011; Lavoie Smith et al., 2013; Lavoie Smith et al., 2011; Park et al., 
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2011). Despite the good validity scores of the sensory section of the NCI-CTCAE, it fails to 
predict CIPN compared to other instruments such as the Patient Neurotoxicity Questionnaire 
(PNQ) (Shimozuma et al., 2012). 
To fill the gap of deficient patient reported CIPN screening instruments, the National 
Cancer Institute developed a new patient reported instrument called PRO-CTCAE (Dueck et al., 
2015; Hay et al., 2014). The internal consistency was high with an intra-class correlation 
coefficient of 0.76; the validity was found to be satisfactory when correlating it with a health 
related quality of life measure (r= 0.34) (Dueck et al., 2015). This standardized approach to 
CIPN screening has been widely adapted in clinical settings, but is of little use in understanding 
the specific symptoms a patient may be having, or how CIPN is affecting their daily life. 
CIPN Assessment 
 
After the screening process for CIPN is complete, a more comprehensive approach is 
needed. This approach includes medical history, symptom review, and physical exam. Further 
assessment includes the use of CIPN objective assessment instruments and/or subjective 
instruments. Some of the instruments use combined subjective/objective measures such as the 
TNSr. 
A comprehensive neurologic clinical assessment is the first step in understanding the 
status of CIPN. It consists of subjective questions followed by a thorough physical exam. The 
subjective part consists of relevant questions appropriate for patient medical history. Some of 
these questions address history of stroke, memory ability, gait, falls, and senses of vision and 
hearing (Corey-Bloom & David, 2009). 
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The second step in the objective neurologic evaluation is to check the gait, muscle 
strength, manual dexterity, vibration sensation, and deep tendon reflexes. Vision, hearing, and 
memory are added in the elderly patients (Corey-Bloom & David, 2009). Gait testing includes 
having patients rise from a chair without using their arms, walk on tiptoes, heels, and tandem for 
10-20 feet. Normally the gait is smooth, rhythmic, and effortless. The hand opposite arm swing 
is coordinated, and turns are smooth (Jarvis & Jarvis, 2004). 
Muscle strength can be done on upper or lower extremities. It is rated from 5 to 0. The 
rating is as follows: 5(Movement against full resistance of examiner), 4(Movement against some 
resistance), 3(Movement against gravity, not resistance), 2(Movement only with gravity 
eliminated), 1(A flicker or trace of voluntary movement), 0(No voluntary movement). 
Deep tendon reflexes are assessed to check the homeostasis between the nerves, the 
cerebral cortex, and the spinal cord. The most commonly used scales to assess deep tendon 
reflexes are the Mayo Clinic Reflex Scale (rated from -4 to +4) and the National Institute of 
Neurological Disorders and Stroke scale (NIND) (rated 0: absent to 4: reflex enhanced more than 
normal or clonus). The NIND inter-observer reliability was assessed using Kappa coefficient and 
was up to 0.89 (Litvan et al., 1996). In 1990, 28% of the providers using the Mayo Clinic Reflex 
disagreed on the rating by two or more points (Stam & van Crevel, 1990). In another study, the 
highest inter-observer reliability Kappa was found to be 0.29 (Manschot, van Passel, Buskens, 
Algra, & van Gijn, 1998). Given the doubts regarding the reliability of conventional deep tendon 
reflexes scales, a new measure was developed that involved testing the use of electromyographic 
deep tendon reflexes. This measure uses a conventional reflex hammer connected by a wire to a 
myography machine. In 2009 study, this instrument detected neuropathy in 60% of patients that 
the conventional method failed in this detection (Sharma, Saadia, Facca, Resnick, & Ayyar, 
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2009). Once the initial physical exam is done, the provider may choose to move to other 
objective assessment measures instruments. 
Objective CIPN Assessment 
 
Objective assessment includes measures of sensory quantification and use touch 
sensation, bump detection, pressure sensation. It also includes direct testing of nerves either by 
biopsy, ultrasound or nerve conduction studies. 
Sensory Quantification. Touch sensation testing can either be done by Semmes- 
Weinstein (von Frey) monofilament, pumps detection device, weighted needle device, or 
Pressure-Specified Sensory Device. The Semmes-Weinstein monofilaments have different 
weights and are usually presented in a kit. The monofilament weight can range from 0.02 grams 
to 300 grams (Kosturakis et al., 2014; Ruhdorfer et al., 2015; Ward et al., 2014).The normal 
sensory threshold is 0.05 gram on the hands (da Silva Simao, Teixeira, Souza, & de Paula Lima, 
2014) and 6 gram on the feet (Thomson, Potter, Finch, & Paisey, 2008). 
The bumps detection device has glass plates with variant elevated bumps on them. The 
patient uses his/her index finger of their dominant hand to identify the smallest bump. The 
detection threshold is determined to be the smallest bump correctly identified in sequence to the 
next two higher bumps. In a comparison between healthy individuals and patients receiving 
chemo, plates containing pumps with a diameter of 550 millimeters (mm) and height ranges from 
2.5-26 mm. In a study, the mean bump detection threshold for CIPN patients was 6.30mm but 
only 3.3mm for volunteers (P<.01) (Kosturakis et al., 2014). 
Pressure sensation can be tested by using either the weighted needle device or Pressure- 
Specified Sensory Device. The weighted needle device weights range from 8 to 128 g. While 
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pressure is applied for one second in ascending order, patients are instructed to state whether the 
sensation produced by each stimulus is that of touch, pressure, sharpness, or pain. The sharpness 
detection threshold is defined as the mean force deemed sharp or painful (Kosturakis et al., 
2014). The Pressure-Specified Sensory Device has two rounded prongs, the pressure is applied to 
the skin by both prongs, and the patient presses a red button connected to the machine indicating 
the feeling of pressure difference between the two prongs (Ruhdorfer et al., 2015). 
In a study reported in 2016, some quantitative sensory measures (cold detection, heat 
detection, and cutaneous detection) were tested on a cohort of 30 patients correlated with the 
NCI-CTCVE. No reliability data was found, but validity was tested by Pearson correlation 
coefficient. Moderate correlations between cold detection threshold r =.50, heat detection 
threshold r=0.39, and cutaneous detection threshold r=0.42 were described (Reddy et al., 2016). 
Direct Nerve Testing. Direct nerve testing can be done by confocal microscopy of the 
skin or cornea, skin ultrasound, skin biopsy, nerve biopsy, or nerve excitability. Confocal 
microscopy is a newer laser imaging technique for visualizing changes in skin structure that can 
identify CIPN. This technique was used in a cohort of multiple myeloma patients and compared 
to sensory and motor perception using skin temperature, grooved pegboard test, monofilaments, 
and bumps detection test. Significant differences were found when comparing healthy 
individuals to individuals who received chemotherapy, which supports validity (Kosturakis et al., 
2014). In another study, similar results were obtained when corneal nerve microscopy was 
correlated with the cumulative dose of chemotherapy with a resulting strong, negative correlation 
(-0.8) (Ferdousi et al., 2015). 
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A skin biopsy can be done to test for small fiber and intraepidermal nerve fiber density. 
This method can be approved by insurance in cases of unidentified neuropathy etiology and has 
been tested against other neuropathy assessment methods and shown to be a good quantitative 
measure. Direct nerve visualization can be done by direct ultrasound using a laser Doppler 
imager (Sharma, Venkitaraman, Vas, & Rayman, 2015). 
Small fiber neuropathy can also be tested using the Sudoscan (a 3-min test), which is a 
machine used to measures the Electrochemical Skin Conductance (ESC) measured in 
milliseconds (ms). This is a non-invasive instrument applied to either the hands or the feet. In 
one study, a comparison was done between Sudoscan and the Total Neuropathy Score-Clinical 
(TNSc) (7 item instrument) on patients who received oxaliplatin, paclitaxel, other drugs, or both 
drugs. For patients receiving oxaliplatin, the mean hands ESC changed from 73ms to 63ms, feet 
ESC from 77ms to 66ms, while TNSc mean changed from 2.9 to 4.3. For patients receiving 
paclitaxel, values of both hands and feet with a corresponding TNSc of <2, the ESC changed 
from 70ms to 73ms. For TNSc of ≥ 6, the ESC changed from 59ms to 64ms, demonstrating the 
validity of the Sudoscan. In this study, there was no reliability data reported (Saad et al., 2016). 
Nerve Electrophysiological Studies. Nerve electrophysiological studies include nerve 
amplitude, electromyography, nerve conduction velocity, and nerve excitability studies (Park, 
Lin, & Kiernan, 2012a). In nerve amplitude, the change of nerve electrical current is measured 
by special equipment. Decreased nerve amplitude can indicate a decrease in nerve conduction 
and thus some form of neuropathy. The electromyography uses a similar approach but testing 
both nerve and muscle function. 
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Similarly, nerve conduction velocity (speed) and nerve excitability (reaction to nerve 
stimulator) can be used. A decline in either, suggests a demyelinating neuropathy indicting 
neuronal harm as seen in CIPN (Kaley & Deangelis, 2009). The usual sites for measuring nerve 
conduction in CIPN are the peroneal, tibial, sural, median, and superficial radial nerves (Park et 
al., 2013). In a study using nerve excitability, it was found that there is a 90-100 millisecond 
excitability difference between patients who received chemotherapy and patients who did not. 
This is good evidence for instrument validity (Park et al., 2012a). 
Despite the objectivity of these studies, they still lack patient input and do not address 
patients’ experience. It is crucial that we find an assessment instrument that is comprehensive, 
objective, and adequately reflects CIPN symptoms. 
Subjective CIPN Assessment 
 
Subjective assessment instruments use patient questionnaires and may address one or 
more of the following issues: neuropathy symptoms, quality of life (QOL), patient functioning, 
or interference with life. Examples of these instruments are the Patient Neurotoxicity 
Questionnaire (Kuroi et al., 2008; Shimozuma et al., 2009), the Chemotherapy-Induced 
Peripheral Neuropathy Assessment Tool (Tofthagen et al., 2011) , The Functional Assessment of 
Cancer Therapy/Gynecologic Oncology Group Neurotoxicity scale (Calhoun et al., 2003; 
Griffith et al., 2014; Yoo & Cho, 2014), the Chemotherapy Induced Neurotoxicity Questionnaire 
(CINQ) (Leonard et al., 2005), The Treatment-Induced Neuropathy Assessment Scale (TNAS) 
(Mendoza et al., 2015), the European Organization for Research and Treatment and Cancer 
EROTC-QOL-CIPN-20 (Cull et al., 2001; Lavoie Smith et al., 2013; Padman et al., 2015), the 
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Peripheral Neuropathy Scale (Cavaletti et al., 2003; Cavaletti et al., 2007), and the Rasch-built 
Disability Scale for patients with CIPN (Binda et al., 2013). 
These subjective instruments are important in understanding the symptoms and effects of 
CIPN on QOL. Due to time constrains, unfamiliarity, and discrepancy between the provider & 
patient perception, these instruments are rarely used in the clinical oncology setting (Basch et al., 
2012; Smith et al., 2014; Visovsky et al., 2012). 
The Patient Neurotoxicity Questionnaire (PNQ). The PNQ has two items graded from 
A to E, with A representing no symptoms and E representing worst symptoms. One item is 
sensory and asks about numbness, pain, or tingling. The second item is motor and asks about 
weakness. A feasibility study was done that shows the usefulness of this instrument in making 
treatment decisions (Kuroi et al., 2008). In one study, the sensory item correlated moderately 
with sensory NCI-CTC (r=0.58), FACT-Taxane (r=0.51), while the motor item correlated with 
FACT- Taxane (r=0.57) (Kuroi et al., 2009). In another study, the correlation of the sensory item 
with NCI-CTC was higher than the motor item (r=0.79) (Bennett et al., 2012). This moderate to 
high correlation supports validity for using it to assess CIPN with the limitation of only two 
patient reported items. 
Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT). In 
2011, a new instrument was developed, called the Chemotherapy-Induced Peripheral Neuropathy 
Assessment Tool (CIPNAT). It was developed based on the theory of Unpleasant Symptoms that 
suggests that complete assessment of unpleasant symptoms should include evaluation of 
symptom occurrence, severity, distress, frequency, and interference with daily activities. The 
CIPNAT has two assessment scales. The first is the symptom experience scale comprising nine 
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neuropathy symptoms with their characteristics (occurrence, severity, distress, and frequency). 
Each symptom is answered with yes/no question, and symptom severity, distress, and frequency 
are answered on a 0-10 scale. Total possible score from each symptom is 31. Total for all items 
is 279. The interference with life scale is comprised of 14 items including walking, picking up 
objects, holding into objects, driving, working, participating in hobbies or leisure activities, 
exercising, sexual activity, sleeping, relationships, writing, usual household chores, and 
enjoyment of life. Each item is scored from 0-10 with a total possible score of 140. Content 
validity index was acceptable at 0.95. Discriminant validity data were provided by correlation 
with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity 
scale (FACT/GOG-Ntx) (r = 0.83). High test-retest correlations (r = 0.92, P .001), Cronbach’s 
alpha = .95, and significant item-to-total correlations ranging from 0.38 to 0.70 provided 
evidence of reliability (Tofthagen, McMillan, & Kip, 2011). In a study assessing the effect of 
CIPN, the CIPNAT was found to be a good predictor of hospital anxiety, depression, and 
functional status (Kim, Lee, Kim, & Oh, 2015). 
The Chemotherapy Induced Neurotoxicity Questionnaire (CINQ). The CINQ 
consists of three sections. Those sections are upper extremity symptoms, lower extremity 
symptoms, and oral/ facial symptoms. The first section asks about the presence of tingling (pins 
and needles), numbness, difficulty telling the difference between rough and smooth surfaces, 
difficulty feeling hot things, difficulty feeling cold things, a greater than normal sense of touch 
(i.e. putting on gloves), a greater than normal sense of touch (i.e. putting on gloves), burning pain 
or discomfort without cold, burning pain or discomfort with cold, difficulty identifying objects in 
your hand (i.e. coin), and involuntary hand movements. The second section asks about tingling 
(pins and needles), difficulty telling the difference between rough and smooth surfaces, difficulty 
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feeling hot things, difficulty feeling cold things, a greater than normal sense of touch (i.e. 
discomfort with socks), burning pain or discomfort without cold, burning pain or discomfort with 
cold, and legs feel heavy. The third section asks about the presence of jaw pain, eyelid drooping, 
throat discomfort, ear pain, tingling in mouth, difficulty with speech, eye burning or discomfort, 
loss of any vision, feeling shock/pain down back, problems with breathing (Leonard et al., 2005). 
These questions in these three sections are answered by yes/no. If yes then it asks two 
questions regarding effects on QOL and effects on daily activities. The first is how much of the 
symptoms did you have? Rated from 1 to 5 (Hardly any → Very much, and did the symptoms 
affect your daily activities? Rated from 1to 5 (Hardly at all bothered → extremely bothered). 
The validity of this instrument was evident by the increased symptoms with subsequent 
chemotherapy cycles. No reliability data was reported (Leonard et al., 2005). In another study, 
this instrument was modified and tested against the Functional Assessment of Cancer 
Therapy/Gynecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx) questionnaire. It was 
valid and strongly correlated with (FACT/GOG-Ntx) questionnaire (r=-.7). No reliability data 
was reported (Driessen et al., 2012). 
The Treatment-Induced Neuropathy Assessment Scale (TNAS). The TNAS was 
published in 2015 reporting data collected from 248 patients between 2008 and 2013. The 
instrument consists of 13 items based on other instruments and expert input. The 13 items were; 
numbness/tingling in hands/feet at its worst, cramps in hands/feet at their worst, sensations of 
pins/needles in arms/legs at their worst, trouble walking because of loss of feeling in legs/feet at 
its worst, feelings of coldness in hands/feet/fingers at its worst, difficulty with balance because of 
loss of feeling in legs/feet at its worst, trouble grasping small objects (e.g., buttoning buttons, 
handling coins, holding a pen)at its worst, hot/burning sensations in hands/feet at their worst, 
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swelling in hands/feet at its worst, sensations of electric shock at their worst, discomfort when 
touching things at its worst, discomfort when skin comes into contact with something (e.g., 
blanket, clothing) at its worst, and pain when touching cold things at its worst. The 13 items were 
divided into two subscales a sensory and a motor. Reliability was found to be high with 
Cronbach’s alpha >0.8. Validity was evaluated by correlating it to EROTC-QLQ-CIPN20. 
Correlation with the sensory section was 0.64, and with the motor section was 0.7 (Mendoza et 
al., 2015). 
Despite the availability of multiple CIPN subjective assessment tool, new measures are 
being developed and tested. This stresses both the need for a good instrument and the lack of 
consensus among the researchers and clinicians on the best approach. 
The History of the Total Neuropathy Score in CIPN Assessment 
 
A combination of both subjective and objective assessment measures may give a more 
comprehensive view of CIPN. These methods combine objective assessment with the patient 
subjective assessment which is important to the individual patient experience. The first used 
CIPN assessment instrument that uses combined approaches is the Total Neuropathy Score 
(TNS) (Cornblath et al., 1999). 
The Total Neuropathy Score, published in 1994, was tested and validated to evaluate 
CIPN. It includes patients’ reporting of motor and sensory symptoms, pin sensibility, vibration 
examination, deep tendon reflexes, and nerve conduction studies. The TNS demonstrated good 
inter-rater reliability (0.94) and intra-rater reliability (0.97) (Chaudhry, Rowinsky, Sartorius, 
Donehower, & Cornblath, 1994). In 2003, a modified version of the TNS was developed by 
omitting the nerve conduction studies; it was called the Total Neuropathy Score-reduced (TNSr). 
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The study demonstrated a strong correlation between TNS and TNSr (r=.97). Scores for all items 
of the TNSr and TNS items increased in the study sample after receiving chemotherapy and with 
cumulative dose (Cavaletti et al., 2003). Validity data also was provided in 2006 by comparing 
the TNS to four other measures; The Modified Total Neuropathy Score (mTNS), the Michigan 
Diabetes Neuropathy scores (MDNS), quantitative touch thresholds, and quantitative vibration 
thresholds. A strong correlation was found between the TNS and the mTNS (r=0.99) and a 
slightly weaker correlation between the mTNS and the MDNS (r=0.71). However, this study did 
not report reliability scores (Wampler, Miaskowski, Byl, Rugo, & Topp, 2006). 
A similar approach was done to test a seven item revised version (Total Neuropathy Scale 
clinical (TNSc) in 2010 and 2013. The TNSc items are sensory, motor, autonomic, pin-prick, 
vibration, strength, and deep tendon reflexes. This instrument was subject to multiple methods of 
testing to insure its fit to be used in the clinical setting and its ability to predict patient function. 
Reliability was evidenced by a Cronbach’s alpha of 0.8, and validity was evidenced by 
correlating it to the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group 
sensory sum score (mISS) with a Spearman factor of r=0.7 (Argyriou et al., 2013; Cavaletti et 
al., 2013; Cavaletti et al., 2010). 
In a different line of research, other versions of the TNS were tested. The Total 
Neuropathy Score-reduced (TNSr) consisting of five items and the Total Neuropathy Score- 
reduced-short form (TNSr-SF) consisting of three items. The five items are sensory symptoms 
(the worst proximal extension of tingling, numbness, neuropathic pain), vibration sense, pin 
sensibility, motor strength, and tendon reflexes. The TNSr-SF has the same items excluding the 
motor strength, pin sensibility, and deep tendon reflexes. The TNSr-SF has a neuropathic pain 
item added. These two instruments show good validity to be used in the clinical field. The 
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validity of TNSr was tested by correlating it with the Neuropathy Pain Scale (NPS-CIN) (r= 
0.51) and the sensory NCI-CTC scores (r=0.63) (Lavoie Smith et al., 2011; Smith et al., 2008). 
Inter-rater reliability of the TNSc (a similar measure to TNSr) was found to be 0.8 (Cavaletti et 
al., 2013). 
In a later study, the TNSc was transformed using the Rasch statistical technique to study 
the factors affecting the use of TNSc in clinical practice. It was found that the seven item 
instrument did not fit the Rasch statistical model but when autonomic symptoms and deep tendon 
reflexes (DTR) were removed, the fit improved. Thus it was recommended to remove those 2 
items from the instrument and it was called Rasch-Transformed Total Neuropathy Score clinical 
version (RT-TNSc) (Binda et al., 2015). 
In summary of the literature pertaining to the TNS and its different version, the TNSc is 
valid and reliable with Cronbach’s alpha score up to 0.8 and Spearman correlation up to 0.7 
(Alberti et al., 2014; Binda et al., 2013; Briani et al., 2014; Griffith et al., 2014; Velasco et al., 
2014). The validity of the TNS-SF is documented, but the validity needs further testing. The 
TNSc is an increasingly used instrument which combines both subjective and objective measures 
making it one of the instruments that can be used in the clinical oncology setting (Cavaletti et al., 
2015). 
There are multiple ways to assess CIPN, and concentrated efforts to develop a standard 
assessment instrument have been a focus of research (Binda et al., 2015; Lavoie Smith et al., 
2013; Tofthagen et al., 2011). These include innovative approaches that use subjective 
instruments, objective instruments, or combined (subjective and objective) instruments. On one 
hand, the objective instruments may be hard to use by most health care providers because of the 
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special skills and sophisticated equipment that these instruments require. This is apparent in 
instruments using nerve conduction studies, skin biopsies, ophthalmic testing, or ultrasound 
(Briani et al., 2013; Burakgazi et al., 2011; Ferdousi et al., 2015; Park et al., 2012b). On the other 
hand, subjective instruments are time consuming, which may discourage consistent use in the 
clinical setting (Shimozuma et al., 2009). The only assessment instruments that have combined 
objective and subjective assessment methods are the TNS and its different versions. (Alberti et 
al., 2014; Binda et al., 2015; Briani et al., 2014; Burakgazi et al., 2011; Frigeni et al., 2011; 
Lavoie Smith et al., 2013; Lavoie Smith et al., 2011; Shimozuma et al., 2009; Smith et al., 2008; 
Velasco et al., 2014). The components of various versions of the TNS are outlined in Table 1. 
Table 1. Total Neuropathy Score (TNS) and its versions used in assessing adults. 
 
 Sensory 
Symptoms 
Motor 
Symptoms 
Autonomic 
Symptoms 
Pin- 
Prick 
Muscle 
Strength 
DTR Vibration 
Sense 
Sural 
NCS1 
Peroneal 
NCS1 
 
 TNS X X X X X X X X X  
 TNSc X X X X X X X    
 RT-TNSc X X  X X  X    
 TNSr X   X X X X    
 mTNS X X X X X X X    
 TNSr-SF X      X    
1.NCS: Nerve Conduction Studies. 
 
CIPN Assessment and Patient Function 
 
The assessment of CIPN has been tied to patient function (Binda et al., 2013; Wolf et al., 
2012). Some assessment instruments use function as an integrated part of the assessment 
instrument. Other instruments used that as the effect or the consequence of CIPN. One of these 
instruments is the EORTC quality of life questionnaire to assess chemotherapy-induced 
peripheral neuropathy (EROTC-QLQ-CIPN20). This instrument has three subscales sensory, 
motor, and autonomic. The motor has items addressing writing, and manipulating small objects 
as patients’ function items. The reliability and validity were tested in a 2005 study reporting a 
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Cronbach’s alpha coefficient of 0.82, 0.73 and 0.76 for the sensory, motor and autonomic scales. 
Validity was studied by using expert and patient input, but no statistical results reported (Postma 
et al., 2005). 
Other assessment instruments looked at the patients’ function as a consequence of the 
CIPN. An example is the interference with activity scale of the CIPNAT. It includes items such 
as walking, picking up objects, holding into objects, driving, working, participating in hobbies or 
leisure activities, exercising, sexual activity, sleeping, relationships, writing, usual household 
chores (Tofthagen et al., 2011). 
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CHAPTER THREE: METHODS 
 
This chapter describes the study methods: The design, setting and sample, and measures 
used in the study. It also describes the study procedure, and data management and analysis. 
Design 
 
This is a cross sectional study designed to test the relationship among Total Neuropathy 
Score-reduced, neuropathy symptoms, and function. This instrument is a short composite of 
subjective and objective measures of CIPN. To achieve this goal, a secondary data analysis was 
conducted using data collected from a study entitled Group Acupuncture for Treatment of 
Neuropathy from Chemotherapy (PI: Tofthagen). 
Setting and Sample 
 
The parent study was conducted at Florida Cancer Specialists facility in Largo, Florida. A 
total of 56 patients were included. Inclusion criteria included that patients had to have a cancer 
diagnosis; had received at least one prior treatment with neurotoxic chemotherapy (any taxane, 
platinum based chemotherapeutic agent, vinca-alkaloid, thalidomide, or bortezomib) within the 
past 10 years; not be currently receiving neurotoxic chemotherapy ; be able to speak, read, and 
write in English; have numbness/tingling/or discomfort in the hands or feet with a minimum 
severity score of three on a 0-10 scale; and have written clearance from their oncologist to 
receive acupuncture. Patients were excluded from the study if they are already receiving 
acupuncture for any reason or if they were pregnant or breastfeeding. 
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Measures 
 
The Total Neuropathy Score-reduced 
 
The TNSr includes one subjective item (the worst proximal extension of tingling, 
numbness, neuropathic pain), and four objective items: (pin sensibility, vibration sensibility, 
muscle strength, and tendon reflexes). The tingling symptom extension is scaled from 0 (none) to 
4 (extension above the knee or elbow). To test pin sensibility, a safety pin is used and is scaled 
from 0 (normal) to 4 (reduced above knee or elbow). To test vibration sensibility, a vibrating 128 
Hz tuning fork is used and is scaled from 0 (normal) to 4 (reduced above knee or elbow). Muscle 
strength scaled from 0 (normal) to 4 (paralysis), and deep tendon reflexes scaled from 0 (normal) 
to 4 (all reflexes absent). The total scores of the TNSr range from 0 to 20. The TNSr has 
demonstrated good reliability and validity. The inter-rater reliability was tested resulting in no 
significant difference between two raters (z= -1.13, P<.26). The validity of the TNSr was tested 
by correlating it with the Neuropathy Pain Scale (NPS-CIN) (r=.69) (Smith et al., 2010). 
The Chemotherapy Induced Peripheral Neuropathy Assessment Tool 
 
The CIPNAT has two assessment scales. One is the symptom assessment scale, and the 
other is the interference with activity scale. Validity and reliability of the total CIPNAT were 
tested by administering it to two groups of patients. One group had neuropathy, and the other did 
not. Content validity index generated by a panel of experts was acceptable at 0.95. Convergent 
validity data were provided by correlation with the Functional Assessment of Cancer 
Therapy/Gynecologic Oncology Group Neurotoxicity Scale (FACT/GOG-Ntx) (r = 0.83, P < 
.001) and differences between the compared groups (t = 7.66, P < .001) provided evidence of 
discriminant validity. High test-retest correlations (r = 0.92, P < .001), Cronbach’s alpha = .95, 
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and significant item-to-total correlations ranging from 0.38 to 0.70 provided evidence of 
reliability (Tofthagen et al., 2011). 
The Symptom Assessment Scale. The symptom experience scale has nine neuropathy 
symptoms with their characteristics (occurrence, severity, distress, and frequency). The patients 
indicate whether each symptom is present by answering a yes/no question and if yes, the 
symptom description items are answered on 0-10 scales. The total possible score from each 
symptom is 31. The total score for all items is 279. 
Discriminant validity of the symptom experience scale was tested by comparing two 
groups of patients (one group had neuropathy and the other group did not) (t = 8.81, P < .001). A 
strong evidence of reliability was found by correlating a test-retest results (r = 0.89, P < .001). 
Internal consistency Cronbach’s alpha coefficients were high for the symptom experience items 
(alpha = .93). 
The Interference with Activity Scale. The interference with activity scale has 14 items 
including walking, picking up objects, holding into objects, driving, working, participating in 
hobbies or leisure activities, exercising, sexual activity, sleeping, relationships, writing, usual 
household chores, and enjoyment of life. Each item is scored from 0-10 with a total possible 
score of 140. Validity was tested for the interference with activity scale (t=4.81, p<.001), test- 
retest reliability(r = 0.93, P < .001). Internal consistency was demonstrated using Cronbach’s 
alpha (alpha = .91) (Tofthagen et al., 2011). 
Procedures 
 
A nurse practitioner approached potential patients about the study, determined eligibility, 
explained the risks and benefits, answered questions, and obtained written informed consent. 
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Participants were in the study for a total of 8 weeks. Patients in the parent study all received 
acupuncture twice a week for four weeks. The study had a waitlist controlled design and 
participants provided data at enrollment, four weeks, and eight weeks. Only baseline data were 
included in this secondary analysis. All study data were collected by a nurse practitioner working 
on the study, or the principle investigator, who is also a nurse practitioner. 
Institutional Review Board Approvals 
 
The parent study was approved by the University of South Florida Internal Review Board 
(IRB). University of South Florida IRB approval was also obtained for this secondary data 
analysis. 
Data Management and Analysis 
 
This study aimed to evaluate the relationship between the Total Neuropathy Score- 
reduced and patients’ function, as measured by the interference scale of the Chemotherapy- 
Induced Peripheral Neuropathy Assessment Tool. It also aimed to evaluate the relationship 
between the Total Neuropathy Score-reduced and neuropathy symptom experience, as measured 
by the symptom experience scale of the Chemotherapy-Induced Peripheral Neuropathy 
Assessment Tool. 
To achieve these aims, secondary data analysis was done for data obtained from Dr. 
Tofthagen (PI). Baseline data from this study involving 56 cancer patients were used. Data were 
kept in a passcode secured cloud account, and the passcode was not shared with any one. Data 
were de-identified, cleaned as needed and screened for outliers and missing data. 
Data analysis was conducted using the Software Package for the Social Sciences 
version 24. The sample was described using means, standard deviations, frequencies, and 
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percentages. Total scores on the TNSr, CIPNAT symptom experience scale and CIPNAT 
interference scale were calculated. To address Aim 1, to evaluate the relationship between the 
Total Neuropathy Score-reduced and patients’ function, as measured by the interference with 
activity scale of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, 
correlations between total scores on the TNSr and total scores on the interference scale of the 
CIPNAT were calculated. 
To address Aim 2, to evaluate the relationship between the Total Neuropathy Score- 
reduced and neuropathy symptom experience, as measured by the symptom experience scale of 
the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, correlations between total 
scores on the TNSr and total scores on the symptom experience scale of the CIPNAT were 
calculated. 
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CHAPTER FOUR: RESULTS 
 
This Chapter presents the statistical results of the analysis in three parts. The first part 
presents the demographic characteristics of the sample, including the age, gender, marital status, 
total years of education, race, and employment status. The second part presents the total scores of 
the TNSr and the CIPNAT; their means and standard deviation (SD). The third part presents the 
correlations between the TNSr, CIPNAT, interference scale of the CIPNAT, and symptom 
experience scale of the CIPNAT. 
Demographics 
 
The participants’ ages ranged from 40 to 86 years old with a mean of 65 and SD of 10.2. 
 
They were about 70% females, 60% married, and all of them had at least 12 years of formal 
education. Eighty nine percent were white while the rest were minorities. About half of them 
were retired and one fourth still working full time. The percentage of participants with GI 
malignancies was 21.7 % and with breast cancer 37%. About half of the participants received a 
taxane (48.2%), and 35.7% received platinum based chemotherapy, either cisplatin or oxaliplatin 
(Table 2). 
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Table 2. Frequencies and percentages for gender, marital status, 
years of education, race, and employment status. (n=56) 
 Frequency Percentage 
Gender Male 17 30.4 
 Female 39 69.6 
Marital Status Single 7 12.5 
 Married/Partnered 34 60.7 
 Divorced 10 17.9 
 Separated 1 1.8 
 Widowed 3 5.4 
Years of education 12 23 41.1 
 13 2 3.6 
 14 12 21.4 
 15 1 1.8 
 16 12 21.4 
 18 3 5.4 
 19 1 1.8 
 20 1 1.8 
Race Asian 2 3.6 
 African American 2 3.6 
 Hispanic 2 3.6 
 White/ Caucasian 50 89.2 
Employment Full Time 13 23.2 
Status  
Part Time 
 
2 
 
3.6 
 On Leave 2 3.6 
 Retired 32 57.1 
 Disabled 6 10.7 
Type of cancer GI 12 21.4 
 Breast 21 37.5 
 GYN 3 5.4 
 Prostate/Testicular 5 7.1 
 Lung 5 8.9 
 Lymphoma 3 5.4 
 Other 8 14.3 
Type of Taxane 27 48.2 
chemotherapy  
Platinum 
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35.7 
 Vinca 3 5.4 
 Multiple 6 10.7 
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Table 3.Scores of the Study Instruments 
 
 
 
 n Range Mean Std. Deviation 
TNSr (total score) 56 2-14 7.9286 3.12094 
Symptom Experience Scale of the 
CIPNAT 
53 24-279 152.2830 59.95812 
Interference with Activity Scale 
of the CIPNAT 
52 0-114 57.6923 33.27281 
 
 
Scores of the Study Instruments 
 
Total score of the TNSr ranged from 2 to 14.00 (0-20 possible scores) with a mean 
of 7.92 (SD 3.12). Scores on the symptom experience scale of the CIPNAT ranged from 24 to 
279 (0-279 possible scores) with a mean of 152.2 and (SD 59.9), while scores on the interference 
scale of the CIPNAT ranged from 0 to 114 (0-140 possible scores) with a mean of 57.6 (SD 3.2) 
The Correlation between the TNSr, the CIPNAT, Patients’ Function, and Neuropathy 
Symptom Experience 
All correlations between the total scores of the study instruments were positive and 
significant. The correlation between the total scores of the TNSr and the total scores of the 
CIPNAT was weak and significant (r=.32, P<0.05). The TNSr total scores were weakly 
correlated with the neuropathy symptom experience scale (r=.344, P<0.01), while the correlation 
between the total TNSr and the interference with activity scale was weak (r=.289, P<0.05). 
Higher correlations were identified between the symptom extension item of the 
TNSr and the two CIPNAT subscales. The correlation with the symptom experience scale of the 
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CIPNAT was r=.355 (p<0.01), while the correlation between the symptom extension item of the 
TNSr and interference with activity scale of the CIPNAT was r=.412, p<0.01). The correlations 
of the rest of individual TNSr physical exam items with the CIPNAT scales were weak (Table 
4). 
 
Table 4. Pearson correlations between the individual items of the TNSr, CIPNAT 
(total scores), symptom experience scale of the CIPNAT, and Interference with 
Activity Scale of the CIPNAT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
score) 
 
 
 
**. Correlation is significant at the 0.01 level (1-tailed). 
*. Correlation is significant at the 0.05 level (1-tailed). 
  
 
CIPNAT (Total 
Symptom Experience 
Scale of the CIPNAT 
Interference with 
Activity Scale of the 
Score)  CIPNAT 
Symptom Pearson Correlation .395** .355** .412** 
Extension Sig. (1-tailed) .002 .005 .001 
 n 50 53 52 
Pin Sensibility Pearson Correlation .050 .141 -.009 
 Sig. (1-tailed) .366 .157 .476 
 n 50 53 52 
Vibration Pearson Correlation .080 .061 .095 
Sensibility Sig. (1-tailed) .289 .332 .251 
 n 50 53 52 
Muscle Pearson Correlation .297* .296* .311* 
Strength Sig. (1-tailed) .018 .016 .012 
 n 50 53 52 
Deep Tendon Pearson Correlation .154 .191 .105 
Reflexes Sig. (1-tailed) .143 .086 .229 
 n 50 53 52 
TNSr (total Pearson Correlation .320* .344** .289* 
Sig. (1-tailed) .012 .006 .019 
56 50 53 52 
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CHAPTER FIVE: DISCUSSION 
 
This Chapter discusses the findings of CIPN instruments, the relationship between the 
TNSr and the CIPNAT and its subscales. Study strengths and limitations, future research and 
clinical application are also discussed. 
One of the main goals for evaluating CIPN assessment instruments is to find instruments 
that can be easily used in the oncology clinical setting, but provide adequate understanding of the 
diverse aspects of CIPN. Despite the decades-long research and the creation of multiple 
instruments, this study did not yield an instrument that can meet the requirements of easy usage 
and comprehensiveness. These study findings are similar to the few studies comparing objective 
and subjective instruments (Alberti et al., 2014; Briani et al., 2013; da Silva Simao et al., 2014; 
Pereira et al., 2016; Reddy et al., 2016; Sharma et al., 2015). 
The Findings of CIPN Instruments 
 
It was noted that some participants choose the maximum scores for the items of 
symptom experience scale of the CIPNAT which is resulted in a total score of 279 explaining the 
level of their symptoms. Although the time line for chemotherapy treatment to this study 
assessment was not collected, this is an important factor in the understanding of their symptoms. 
In some studies, it was noted that some CIPN might improve after six months but some patient 
may have chronic lingering symptoms resistant to treatment (Argyriou et al., 2005). Although 
some participants rated their symptom experience at the maximum score, none of them had 
maximum scores of the TNSr or their interference with activity scores. This is an example of the 
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incongruence between objective and subjective CIPN instruments. It appears that patients can 
have severe symptoms with minimal interference with function and without objective evidence 
of symptoms. 
The Relationship between the TNSr and the CIPNAT 
 
In this study, the correlation between the TNSr and the CIPNAT were found to be 
positive, weak and significant. These results echo similar studies that compared objective and 
subjective instruments. In a 2013 study, the mean TNSc increased from 1.07 to 5.13 after 
chemotherapy treatment and 60% of the same sample had documented nerve damage (Briani et 
al., 2013). In another study, vibration sensation had a positively high moderate correlation with 
the patient reported quality of life QLQ-CIPN20 (r=0.67) (Sharma et al., 2015). The significant 
correlation between The TNSr and the CIPNAT makes the prospect of using the TNSr in the 
clinical oncology setting a reasonable augmentation for the assessment process. 
The use of pure subjective or objective CIPN instruments does not yield a perfect 
understanding of the problem, and apparently neither does combining them (Alberti et al., 2014). 
There are incongruences between patients’ reporting and providers’ judgment (Bennett et al., 
2012). Therefore, providers should not rely on objective assessment alone, but should 
incorporate information from patients into their assessment. In addition, the objective 
instruments are not readily available for the average oncology nurse practitioner or physician. 
The Relationship between the TNSr and Patients’ Function 
 
In this study, there was a weak correlation between the TNSr and the interference 
with activity scale of the CIPNAT, which suggests that basic neurologic assessments such as 
DTRs, vibratory sensation, and pin-prick sensation, all items on the TNSr, are insufficient to 
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identify difficulties with functioning that patients may be experiencing as a result of CIPN. 
Cancer treatment can lead to devastating effects on patients’ function; thus, a careful assessment 
before any treatment is needed (Tan, Chamie, Daskivich, Litwin, & Hu, 2016). The effects of 
CIPN on patients’ function led some researchers to consider assessing this function through the 
prism of CIPN assessment instruments. The CIPNAT interference with activity scale (14 items) 
is a subjective patient function assessment tool. The Rasch-built overall disability scale for 
patients with chemotherapy-induced peripheral neuropathy (22 items) is also a subjective 
instrument that is merely dedicated to the assessment of patient function in the presence of CIPN. 
While the length of those subjective instruments may discourage the providers from using them 
in the day-to-day clinical oncologic setting, the objective instruments are not sufficient alone to 
identify functional impairments or recognize individuals at risk for fall or other injuries. 
The Relationship between the TNSr and Neuropathy Symptom Experience 
 
The overall relationship between the TNSr and the symptom experience scale of the 
CIPNAT was weak. This is the same trend that was seen when relating the TNSr with patients’ 
function. The only item that had slightly higher correlation is the symptom extension as they 
both measure subjective input of the patients (r=.35, P<.01). The expansion of this single item to 
three items, as seen in the TNSr-SF, can be helpful but needs further studying (Lavoie Smith et 
al., 2011). 
Study Strengths and Limitations 
 
Limitations of this study are mainly related to the small sample size. A larger sample 
might have contributed to more sophisticated analysis techniques including regressions and 
predictions to better understand the relationships among the study instruments. Regression might 
have given us further insight on certain items of the instruments leading to compressing those 
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instruments and making them shorter and easier to use. Also, time line after receiving 
chemotherapy was not collected; these data are important as CIPN is affected by both 
chemotherapy type and time after chemotherapy treatment. Participants in this study all were 
required to have at least moderate neuropathy, which developed following neurotoxic 
chemotherapy. It is thought that taxane neuropathy improves after two years, but neuropathic 
pain can linger in a phenomena called coasting, seen mainly with platinums (Izycki et al., 2016). 
The sample of this study had some participants that received chemotherapy up to 10 years prior 
to participation, which suggests that this group had neuropathy that did not follow the typical 
pattern and many in this sample could have been among the approximately 20% of people who 
will have permanent neuropathy following chemotherapy, or may have had other unknown 
factors contributing to their neuropathy. 
Another limitation is the lack of data regarding inter-rater reliability in this study. Even 
though a consistent scoring method is used for this objective measure, there is some subjectivity 
involved with most items on the TNSr, such as reflexes and muscle strength, even when 
consistent protocols are used, as they were in this study. Evaluation of inter-rater reliability was 
planned but the ARNP who initially conducted the assessments left the study abruptly. The 
objective physical exam portion of the TNSr needs to be done consistently by the same trained 
providers. The reliability of the DTR is questionable when done by multiple clinicians (Binda et 
al., 2015; Sharma et al., 2009). 
Future Research and Clinical Application 
 
Future research involving a larger study sample would help in doing some stratified 
analysis. It should help in differentiating the findings among different participants with various 
cancer types, various chemotherapy agent. It is also helpful to differentiate between participants 
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based on time frame after receiving chemotherapy. The results of this study stress the need to use 
instruments with subjective patient input as well as providers’ objective input. 
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CONCLUSION 
 
The study found that there is a positive weak relationship between the TNSr and the 
neuropathy symptoms as measured by the symptom experience scale of the CIPNAT. A positive 
weak relationship was found between the TNSr and patients’ function as measures by the 
interference with activity scale of the CIPNAT. These results support the need to incorporate 
patient reported data into CIPN assessment, and do not support the use of clinical evaluation as a 
superior method of CIPN assessment. The use of assessment instruments needs to be based on 
the purpose of the assessment and possible interventions. The discipline of nursing, with a focus 
on alleviating symptoms, prevention of falls, and maintaining a safe environment, must devote 
significant time and attention to aspects of CIPN assessment that will guide nursing practice. 
Therefore, healthcare professionals interested in helping patients better control their symptoms or 
improve their functional status may be better served using subjective instruments such as the 
CIPNAT. Further research is needed to develop and evaluate instruments that are 
comprehensive, reliable, valid, and practical for use in clinical settings. 
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Demographic Data Form 
 
 
 
Participant ID: 
 
 
1. What is your 
current age? 
 
 
2. What is your gender? Male  Female    
 
3. What is your marital 
status?  Single 
    Married/partnered 
    Divorced 
    Separated 
    Widowed 
 
4. How many years of formal education have you 
completed? 
 
Example: 12 = high school graduate, 14 = associate degree or 
technical school, 16 = baccalaureate degree 
 
5. What is your race or ethnicity? (check all that apply) 
 
    American Indian/Alaskan Native 
    Asian 
    African American 
    Hispanic 
    Native Hawaiian/Pacific Islander 
    White/Caucasian 
    Other or Unknown 
 
6. What is your current employment status? (check all that apply) 
 
    Full time employee 
    Part time employee 
    On leave of absence 
    Retired 
    Disabled 
    Full time student 
 
 
7. What kind of cancer are you seen at Florida Cancer Specialists for?   
51  
Description and scoring of TNSr 
Score 0 1 2 3 4 
Symptom 
extension 
none Symptoms 
limited to 
fingers or toes 
Symptoms 
extend to ankle 
or wrist 
Symptom 
extension to 
knee or elbow 
Symptoms 
above knee or 
elbow 
Pin Sensibility Normal Reduced in 
fingers/toes 
Reduced up to 
wrist/ankle 
Reduced up to 
elbow/knee 
Reduced above 
elbow/knee 
Vibration 
Sensibility 
Normal Reduced in 
fingers/toes 
Reduced up to 
wrist/ankle 
Reduced up to 
elbow/knee 
Reduced above 
elbow/knee 
Muscle 
Strength 
Normal Mild weakness Moderate 
weakness 
Severe 
weakness 
Paralysis 
Deep Tendon 
Reflexes 
Normal Ankle reflex 
reduced 
Ankle reflex 
absent 
Ankle reflex 
absent 
All reflexes 
absent 
1 of 2  
Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT) 
Cindy Tofthagen, PhD, ARNP 
 
Directions : Circle your answers to the questions below. Start by answering questions 1-4. If your answer is “yes” to any of the first four questions, please 
complete the entire questionnaire. If your answer is “no” to all of the first four questions, you may stop. Thank you for completing this evaluation. 
Answer B-D for each symptom that you mark as “yes” under A on the left 
A        B           C           D      
Since your chemotherapy, have you 
developed: 
     How Severe is it?     How distressing (emotionally 
upsetting) is it? 
 How frequently do you have it? 
   Not at all 
Severe 
   Extremely 
Severe 
Not at all 
Distressing 
   Extremely 
stressing 
Never  50% 
 the time 
ways 
1. Numbness in the fingers/hands? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
2. Numbness in the toes/feet? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
3. Tingling in the fingers/hands? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
4. Tingling in the toes/feet? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
5. Discomfort in the fingers/hands 
or toes/feet? 
no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
6. Sensitivity to cold temperature? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
7. Muscle or joint aches? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
8. Weakness in the arms or legs? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
9. Trouble with your balance? no yes 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 
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Chemotherapy Induced Peripheral Neuropathy Assessment Tool -Abbreviated (CIPNAT-A) 
Cindy Tofthagen, PhD, ARNP 
 
 
 
 
How much are the symptoms you reported interfering with: 
Not at all Completely 
Interfering Interfering 
Dressing (buttoning, zipping, etc) 0 1 2 3 4 5 6 7 8 9 10 
Walking 0 1 2 3 4 5 6 7 8 9 10 
Picking up objects 0 1 2 3 4 5 6 7 8 9 10 
Holding onto objects 0 1 2 3 4 5 6 7 8 9 10 
Driving 0 1 2 3 4 5 6 7 8 9 10 
Working 0 1 2 3 4 5 6 7 8 9 10 
Participating in hobbies or leisure activities 0 1 2 3 4 5 6 7 8 9 10 
Exercising 0 1 2 3 4 5 6 7 8 9 10 
Sleeping 0 1 2 3 4 5 6 7 8 9 10 
Relationships with other people 0 1 2 3 4 5 6 7 8 9 10 
Writing 0 1 2 3 4 5 6 7 8 9 10 
Usual household chores 0 1 2 3 4 5 6 7 8 9 10 
Enjoyment of life 0 1 2 3 4 5 6 7 8 9 10 
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